H. Lundbeck A/S

FDA approves Rexulti (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia

Young adult patients* with schizophrenia show improved functioning and health-related quality of life with Abilify Maintena® (aripiprazole once-monthly) compared with paliperidone palmitate

Major shareholder announcement

Total number of voting rights and share capital in H. Lundbeck A/S as of 31 May 2015

Lundbeck increases its share capital by 186,676 shares (0.0950% of outstanding shares)

Solid performance in the first quarter of the year. Full year guidance maintained

Kåre Schultz appointed new president and CEO of Lundbeck

Major shareholder announcement

Lundbeck held its Annual General Meeting on 25 March 2015 at the company’s registered office

European CHMP issues positive opinion for a label update of Brintellix® (vortioxetine) to reflect its effect on certain aspects of cognitive function in patients with depression

Total number of voting rights and share capital in H. Lundbeck A/S as of 28 February 2015

Notice of annual general meeting

H. Lundbeck A/S increases its share capital by 40,480 shares (0.0206% of outstanding shares) as a result of employee warrant exercise

Annual Report 2014 for H. Lundbeck A/S

Performance in 2014 positions Lundbeck well for 2015 and beyond

Lundbeck to research link between immune system and brain diseases

Lundbeck discontinues further development of desmoteplase; 2014 profit guidance range narrowed

Imaging (fMRI) study reveals Brintellix® (vortioxetine) affects the underlying brain systems involved in working memory in people remitted from depression

Otsuka and Lundbeck´s brexpiprazole demonstrates statistically significant effects in New Phase III Studies in adult patients with schizophrenia presented at the American College of Neuropsychopharmacology annual meeting

Otsuka and Lundbeck present Phase III data on brexpiprazole as adjunctive therapy in adult patients with major depression at The American College of Neuropsychopharmacology annual meeting

US FDA approves the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension to describe new clinical data for the treatment of acutely relapsed adults with schizophrenia

Total number of voting rights and share capital in H. Lundbeck A/S as of 30 November 2014

Ulf Wiinberg resigns as CEO of Lundbeck

H. Lundbeck A/S increases its share capital by 7,347 shares (0.0037% of outstanding shares) as a result of employee warrant exercise

Solid growth of New Products, positive pipeline development and financial outlook maintained

Aripiprazole once-monthly shows superior effectiveness to paliperidone palmitate once-monthly on quality of life scale in patients with schizophrenia

Lundbeck presents new efficacy and safety data analyses for desmoteplase in patients with acute ischaemic stroke

US FDA accepts Otsuka and Lundbeck’s filing for review of brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression

European launch of Brintellix commences in Denmark

Lundbeck announces availability of NORTHERA™ in the U.S.